Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176865 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplant for Immunologic or Histiocytic Disorders
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00176865 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 19 participants.
The verdict
NCT00176865, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU), anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell transplant, and a post transplant regimen of Cyclosporin A (CsA) in patients with immunologic or histiocytic disorders. The researchers hypothesize that this regimen will have a positive effect on post transplant engraftment and the incidence of graft-versus-host-disease (GVHD). Patients will be randomized biologically into one of 3 arms based upon donor availability: (a) human leukocyte antigen (HLA) genotypic matched sibling donor, (b) HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor, (c) two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Anti-thymocyte globulin (ATG)
- PROCEDURE Stem Cell Transplant
- DRUG Campath 1H
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2002-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176865
The ClinicalTrials.gov registry entry for NCT00176865 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00176865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176865 about?
NCT00176865 is a clinical study titled "Stem Cell Transplant for Immunologic or Histiocytic Disorders". This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU), anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell transplant, and a post transplant regimen of Cyclosporin A (CsA) in patients with immunologic or histiocytic disorders. T...
What is the current status of trial NCT00176865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2002-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00176865?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Anti-thymocyte globulin (ATG) (DRUG), Stem Cell Transplant (PROCEDURE), Campath 1H (DRUG).
Who is sponsoring clinical trial NCT00176865?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.